Trypan blue deemed safe in vireoretinal surgery

Article

According to data recently published, trypan blue (TB) doesn't cause injury to the retinal pigment epithelium (RPE) when used in vitreoretinal surgery...

According to data recently published in the Journal Retina, trypan blue (TB) doesn't cause injury to the retinal pigment epithelium (RPE) when used in vitreoretinal surgery.

Dr Ehab Abdelkader et al. from the Grampian University Hospitals-NHS Trust, Aberdeen, UK, examined the in vivo safety of TB in patients treated with TB-assisted internal limiting membrane or epiretinal membrane peeling. The study group comprised 21 eyes of 21 patients that had full-thickness macular hole and/or epiretinal membrane. Distance and near visual acuity (VA) were measured along with amplitude of P50 and N95 of the pattern electroretinogram and fundus autofluorescence preoperatively and 6 and 12 months postoperatively.

The researchers found that there was a statistically significant improvement in distance and near VA as well as P50 and N95 amplitude at both post-op follow-ups. Additionally, autofluorescence analysis proved that there was no damage to the RPE as a result of TB.

Based on the results it was concluded that TB does not cause harmful effects in vitreoretinal surgery.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
© 2025 MJH Life Sciences

All rights reserved.